Liver microRNAs: Potential mediators and biomarkers for metabolic and cardiovascular disease?

Peter Willeit, Philipp Skroblin, Stefan Kiechl, Carlos Fernández-Hernando, Manuel Mayr*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

110 Citations (Scopus)

Abstract

Recent discoveries have revealed that microRNAs (miRNAs) play a key role in the regulation of gene expression. In this review, we summarize the rapidly evolving knowledge about liver miRNAs (including miR-33, -33∗, miR-223, -30c, -144, -148a, -24, -29, and -122) and their link to hepatic lipid metabolism, atherosclerosis and cardiovascular disease, non-alcoholic fatty liver disease, metabolic syndrome, and type-2 diabetes. With regards to its biomarker potential, the main focus is on miR-122 as the most abundant liver miRNA with exquisite tissue specificity. MiR-122 has been proposed to play a central role in the maintenance of lipid and glucose homeostasis and is consistently detectable in serum and plasma. This miRNA may therefore constitute a novel biomarker for cardiovascular and metabolic diseases.

Original languageEnglish
Pages (from-to)3260-3266
Number of pages7
JournalEuropean Heart Journal
Volume37
Issue number43
DOIs
Publication statusPublished - 2016

Keywords

  • Biomarkers
  • Cardiovascular disease
  • Lipid metabolism
  • MicroRNAs

Fingerprint

Dive into the research topics of 'Liver microRNAs: Potential mediators and biomarkers for metabolic and cardiovascular disease?'. Together they form a unique fingerprint.

Cite this